Description
Flixotide Evohaler 250mcg contains fluticasone propionate which offers prophylactic treatment for asthma. Also, it helps to prevent asthma attacks in people who need regular treatment. It works by reducing swelling and irritation in the lungs.
Flixotide 50 micrograms Evohaler, Flixotide 125 micrograms Evohaler and Flixotide 250 micrograms Evohaler are pressurised inhalation, suspensions, delivering either 50, 125 or 250 micrograms of fluticasone propionate per actuation, respectively.
Fluticasone propionate given by inhalation offers prophylactic treatment for asthma.
Adults:
- Mild asthma: Patients requiring intermittent symptomatic bronchodilator asthma medication on a regular daily basis.
- Moderate asthma: Patients with unstable or worsening asthma despite prophylactic therapy or bronchodilator alone.
- Severe asthma: Patients with severe chronic asthma and those who are dependent on systemic corticosteroids for adequate control of symptoms. On introduction of inhaled fluticasone propionate many of these patients may be able to reduce significantly, or to eliminate, their requirement for oral corticosteroids.
- Children:
Any child who requires prophylactic medication, including patients not controlled on currently available prophylactic medication. It should be noted that only the 50 microgram device is suitable for the administration of this dose.
